Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miRNA-371a-3p inhibitor
- Development stage
- Preclinical
- Lead developer
- Universitätsklinikum Düsseldorf
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
miRNA-371a-3p inhibitor is a synthetic oligonucleotide designed to inhibit the activity of microRNA-371a-3p (miR-371a-3p). In preclinical research, particularly in testicular germ cell tumors (TGCTs), miR-371a-3p is highly expressed and serves as a sensitive biomarker. Inhibition of miR-371a-3p using antagomirs or inhibitors has been shown to restore cisplatin sensitivity in resistant TGCT cell lines and affect key signaling pathways such as JAK/STAT, TGF-beta, and MAPK. It is primarily utilized as a research-use-only (RUO) laboratory reagent to investigate the molecular functions of miR-371a-3p in vitro.
- Other names
- antagomir-371a-3pantagomir371a-3pantagomir 371a-3phsa-miR-371a-3p inhibitorhsa-miR371a-3p inhibitorhsa-miR 371a-3p inhibitormiR-371a-3p antagomirmiR371a-3p antagomirmiR 371a-3p antagomirmiR-371a-3p inhibitormiR371a-3p inhibitormiR 371a-3p inhibitor
Beyond the preview
Go deeper on miRNA-371a-3p inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miRNA-371a-3p inhibitor.